Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 5

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 5
---
1;                                                                                                           |

| ● | Accutane®                                                                                                                            
 (an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne), licensed in July 2020 and launched in March 2021; |

| ● | Amzeeq®                                                                                                                                
 (minocycline) topical foam, 4% (a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate 
 to severe acne vulgaris in adults and children nine years and older), acquired and launched in January 2022;                           |

| ● | Zilxi®                                                                                                                                  
 (minocycline) topical foam, 1.5% (a topical minocycline treatment for inflammatory lesions of rosacea in adults), acquired and launched 
 in January 2022;                                                                                                                        |

<div align='center'>S-2</div>

| ● | Exelderm®                                                                                                         
 Cream and Solution (a broad-spectrum antifungal intended for topical use), acquired and launched in October 2018; |

| ● | Targadox®                                                                                                               
 (an oral doxycycline drug for adjunctive therapy for severe acne), licensed in March 2015 and launched in October 2016; 
 and                                                                                                                     |

| ● | Luxamend®                                                                                                                                
 (a water-based emulsion formulated to provide an optimally moist healing environment for superficial wounds; minor cuts or scrapes;      
 dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis), acquired in 2021 and launched 
 in 2023.                                                                                                                                 |

Our Strategy We are a highly focused, pharmaceutical company dedicated to developing and commercializing therapies for the treatment of dermatologic conditions that seeks to deliver value to patients, physicians and the healthcare system, as well as to our stakeholders. Our strategic priorities include continuing to augment and grow our product portfolio and organization in order to maximize long-term value creation. This will consist of both commercial execution on our existing product portfolio, including lifecycle management, out-licensing of our current branded products, intellectual property and/or technologies in global markets, as well as investing in additional growth strategies through product and company acquisitions, licensing, or developing new products. An important part of our growth strategy is to identify new business development opportunities, including development stage and commercial drugs that we may acquire from other pharmaceutical companies. We are in various stages of discussion for other opportunities, both commercial and development stage,